OCT 5·SEC EDGARLow
Williams Donald Allen purchased $29K of PALI
Williams Donald Allen purchased 20,000 shares of PALISADE BIO, INC. (PALI) at an average of $1.44 ($1.42–$1.46) across 2 trades over 2026-10-01 to 2026-10-02.
StockNASDAQ · US · USDHealthcare · Biotechnology
$PALI
PALISADE BIO, INC.
Price · $PALIvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $PALI in the last 7 days.
Insider · 30dAll trades →
- Buys
- $29K 2 txs
- Sells
- — 0 txs
Williams Donald Allen2× · $29K
10b5-1 share of filings0%
Top stories · $PALIMore →
AUG 21·stocktitan.net
Palisade Bio (PALI) CEO reallocates 176K shares in gifts
Palisade Bio (PALI) CEO John David Finley gifted 176,800 shares of common stock on August 19, 2026, transferring 88,400 shares to FCW Investments, LLC, which he manages. Post-transaction, he directly holds 129,288 shares and indirectly holds 88,451 shares. The transactions were not under a Rule 10b5-1 trading plan.
AUG 10·SEC EDGAR 8-K
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
PALISADE BIO, INC. (PALI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treat
PALI sentiment & insider activity
Recent PALI coverage spans financial news, insider activity and earnings.
In the last 30 days, PALI insiders filed 2 SEC Form 4 transactions — 2 purchases ($29K) and no sales. The most active reporter was Williams Donald Allen with 2 filings.
What's driving PALI
Small insider purchase may signal confidence but size is modest.
The insider gift disclosure reveals a shift in ownership structure but no immediate cash transaction.
IND clearance plus Phase 2 timing and Phase 1 efficacy highlights increase probability of near-term clinical execution and future readout optionality.
A new 6.0% beneficial ownership disclosure can shift perceived control dynamics and influence near-term positioning around Palisade Bio.
Initiated coverage plus specific clinical and regulatory milestones can support near-term sentiment, but it is not a new trial readout.
AlphAI scores every news story that mentions PALI with an AI model for sentiment and relevance, and aggregates insider trades from PALISADE BIO, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $PALI
Score
Williams Donald Allen purchased $29K of PALI
Williams Donald Allen purchased 20,000 shares of PALISADE BIO, INC. (PALI) at an average of $1.44 ($1.42–$1.46) across 2 trades over 2026-10-01 to 2026-10-02.
1 min readPalisade Bio (PALI) CEO reallocates 176K shares in gifts
Palisade Bio (PALI) CEO John David Finley gifted 176,800 shares of common stock on August 19, 2026, transferring 88,400 shares to FCW Investments, LLC, which he manages. Post-transaction, he directly holds 129,288 shares and indirectly holds 88,451 shares. The transactions were not under a Rule 10b5-1 trading plan.
1 min readPalisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
PALISADE BIO, INC. (PALI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treat
7 min readBlackRock (PALI holder) discloses 6.0% ownership of Palisade Bio common stock
BlackRock, Inc. filed a Schedule 13G showing beneficial ownership of Palisade Bio, Inc. common stock as of June 30, 2026. BlackRock and its business units report 10,436,760 shares, or 6.0% of the class. It reports sole voting power over 10,326,107 shares and sole dispositive power over 10,436,760 shares.
3 min readPalisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
Oppenheimer initiated coverage of Palisade Bio Inc. and said its stock offers exposure to the inflammatory bowel disease market. The company’s lead drug PALI-2108 (PDE4 inhibitor prodrug) showed positive Phase 1a/1b results. The FDA cleared its IND in June for Phase 2 ASCENTRA-UC, with enrollment in 2H 2026 and topline data in 2H 2027. Oppenheimer set a Buy rating and $8 price target.
6 min readPalisade Bio Analyst Sees Lead Drug Can Potentially Bridge Gap in Ulcerative Colitis - Palisade Bio (NASD
Benzinga reports Palisade Bio’s lead drug PALI-2108, a once-daily oral PDE4 inhibitor prodrug, showed positive Phase 1a and 1b results in ulcerative colitis and fibrostenotic Crohn’s disease. The company plans an IND for Phase 2 ASCENTRA-CD in 2H 2026. Analyst Leland Gershell initiated Buy with an $8 price target; Oppenheimer projects peak U.S. sales of $2.6B UC (2040) and $2.8B fibrostenotic CD (2041).
3 min read
Palisade Bio jumps following Oppenheimer outperform initiation (PALI:NASDAQ)
Oppenheimer initiated coverage of Palisade Bio (PALI) with an outperform rating, and the stock rose about 14% in Thursday morning trading. The firm set an $8 price target, implying 321% upside versus the July 22 close. Analyst Lelend Gershell cited potential for PALI-2108.
1 min readBaltera Robert Jr. purchased $89K of PALI
Baltera Robert Jr. purchased 45,000 shares of PALISADE BIO, INC. (PALI) at an average of $1.97 ($1.96–$1.99) across 2 trades over 2026-07-08 to 2026-07-09.
1 min readWednesday’s insider trading: Major buy at Mission Produce By Investing.com
A roundup of July 8, 2026 insider trades reported major buys in Mission Produce (AVO), where Globalharvest Holdings Venture Ltd bought 650,415 shares for about $8.28M at $12.73 avg, and Boundless Bio (BOLD), where Tang Capital bought 57,210 shares for about $141.9K. Major sells included Rocket Lab (RKLB) CEO Peter Beck selling about $286.4M and Dell (DELL) director Egon Durban/Silver Lake selling about $29.9M.
7 min readBaltera Robert Jr. purchased $102K of PALI
Baltera Robert Jr. purchased 50,000 shares of PALISADE BIO, INC. (PALI) at an average of $2.04 ($2.03–$2.05, $0.10M total) across 2 trades over 2026-07-06 to 2026-07-07.
1 min read